WO2022239823A1 - 新型コロナウイルスの変異ウイルスに対する感染症治療剤 - Google Patents
新型コロナウイルスの変異ウイルスに対する感染症治療剤 Download PDFInfo
- Publication number
- WO2022239823A1 WO2022239823A1 PCT/JP2022/020028 JP2022020028W WO2022239823A1 WO 2022239823 A1 WO2022239823 A1 WO 2022239823A1 JP 2022020028 W JP2022020028 W JP 2022020028W WO 2022239823 A1 WO2022239823 A1 WO 2022239823A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- therapeutic agent
- coronavirus
- coronavirus infection
- mutant
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 115
- 241000711573 Coronaviridae Species 0.000 title claims description 54
- 208000035473 Communicable disease Diseases 0.000 title description 6
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 38
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 49
- 229940124597 therapeutic agent Drugs 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 23
- 230000001965 increasing effect Effects 0.000 claims description 22
- 230000003247 decreasing effect Effects 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 230000002068 genetic effect Effects 0.000 claims description 16
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 10
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 9
- 229940126585 therapeutic drug Drugs 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 101710139375 Corneodesmosin Proteins 0.000 claims description 4
- 102100031673 Corneodesmosin Human genes 0.000 claims description 4
- 101710204837 Envelope small membrane protein Proteins 0.000 claims description 4
- 101710145006 Lysis protein Proteins 0.000 claims description 4
- 101710085938 Matrix protein Proteins 0.000 claims description 4
- 101710127721 Membrane protein Proteins 0.000 claims description 4
- 108060004795 Methyltransferase Proteins 0.000 claims description 4
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims description 4
- 108060002716 Exonuclease Proteins 0.000 claims description 3
- 101710141454 Nucleoprotein Proteins 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000005540 biological transmission Effects 0.000 claims description 3
- 102000013165 exonuclease Human genes 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 44
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 44
- 238000000034 method Methods 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 28
- 238000012360 testing method Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 230000000120 cytopathologic effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 6
- 241001493065 dsRNA viruses Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229950008454 favipiravir Drugs 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
- 102100038079 AP2-associated protein kinase 1 Human genes 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 description 3
- 102000004225 Cathepsin B Human genes 0.000 description 3
- 108090000712 Cathepsin B Proteins 0.000 description 3
- 102000004172 Cathepsin L Human genes 0.000 description 3
- 108090000624 Cathepsin L Proteins 0.000 description 3
- 102100039683 Cyclin-G-associated kinase Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 231100000036 EC90 Toxicity 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 101800002870 Helicase nsp13 Proteins 0.000 description 3
- 101000742699 Homo sapiens AP2-associated protein kinase 1 Proteins 0.000 description 3
- 101000886209 Homo sapiens Cyclin-G-associated kinase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 101150094202 MBL2 gene Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 3
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- POOTZJVXDGHNMQ-UHFFFAOYSA-N clathrin A Natural products CC(C)CC=CC(C)C=CC=C(C)CCC1CCCC(C(O)=O)=C1 POOTZJVXDGHNMQ-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 239000002329 esterase inhibitor Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108010028403 hemagglutinin esterase Proteins 0.000 description 3
- -1 hydrochloric Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002911 sialidase inhibitor Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 2
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 231100000645 Reed–Muench method Toxicity 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ARMLOXGBRBHILM-UHFFFAOYSA-N caraphenol A Natural products Oc1ccc(cc1)C2Oc3cc(O)cc4c3C2c5cc(O)cc6OC(C(c7cc(O)cc8oc(c9ccc(O)cc9)c4c78)c56)c%10cccc(O)c%10 ARMLOXGBRBHILM-UHFFFAOYSA-N 0.000 description 2
- ULEJGXIKBFHUOY-PIQPXYRBSA-N caraphenol a Chemical compound C1=CC(O)=CC=C1[C@@H]1[C@@H](C=2C=3[C@H]([C@@H](OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)C=2C=3C4=C(OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)C2=C4C=C(O)C=C2O1 ULEJGXIKBFHUOY-PIQPXYRBSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DARSMUGUKCGKHQ-UHFFFAOYSA-M chembl1256733 Chemical compound O.O.[Na+].[N-]1N=C([N+]([O-])=O)C(=O)N2N=C(SC)N=C21 DARSMUGUKCGKHQ-UHFFFAOYSA-M 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960005102 foscarnet Drugs 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940051184 imdevimab Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229960002418 ivermectin Drugs 0.000 description 2
- YPWHZCPMOQGCDQ-HMGRVEAOSA-N kaempferol 7-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-HMGRVEAOSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 229960002480 nitazoxanide Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 2
- 229960004626 umifenovir Drugs 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonic acid Chemical compound CC1=CC(C)=C(S(O)(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical compound C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 description 1
- HEBOXBAVJPCGPL-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)-2,4,10-trioxatricyclo[3.3.1.13,7]decane-1,5,7-triol Chemical compound C1=C(O)C(OC)=CC(C23OC4(O)CC(O)(CC(C4)(O)O2)O3)=C1 HEBOXBAVJPCGPL-UHFFFAOYSA-N 0.000 description 1
- OXXOVUPTBWXVOT-UHFFFAOYSA-N 3-[5-hydroxy-2-[1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]-3-(hydroxymethyl)-6-methylpyridin-4-yl]-2,4,10-trioxatricyclo[3.3.1.13,7]decane-1,5,7-triol Chemical compound OC1=C(C=C(C=C1)CC(C)C1=C(C(=C(C(=N1)C)O)C12OC3(CC(CC(O1)(C3)O)(O2)O)O)CO)OC OXXOVUPTBWXVOT-UHFFFAOYSA-N 0.000 description 1
- HCDBOXMXKHRPSB-UHFFFAOYSA-N 5-hydroxy-2-iodo-6-methyl-4-(1,5,7-trihydroxy-2,4,10-trioxatricyclo[3.3.1.13,7]decan-3-yl)pyridine-3-carboxylic acid Chemical compound CC1=NC(I)=C(C(O)=O)C(C(OC(C2)(C3)O)(OC2(C2)O)OC32O)=C1O HCDBOXMXKHRPSB-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 208000005989 Arenaviridae Infections Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 208000008371 Bunyaviridae Infections Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- NKGNREWERBOCEP-UHFFFAOYSA-N CC1=NC=C(CO)C(C23OC4(O)CC(O)(CC(C4)(O)O2)O3)=C1O Chemical compound CC1=NC=C(CO)C(C23OC4(O)CC(O)(CC(C4)(O)O2)O3)=C1O NKGNREWERBOCEP-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 101710143544 Griffithsin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- YPWHZCPMOQGCDQ-UHFFFAOYSA-N Populnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=CC(O)=CC=3)OC2=C1 YPWHZCPMOQGCDQ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101800001862 Proofreading exoribonuclease Proteins 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 101500025257 Severe acute respiratory syndrome coronavirus 2 RNA-directed RNA polymerase nsp12 Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124393 anti-influenza virus drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 208000024597 arenavirus hemorrhagic fever Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 229940008411 baloxavir marboxil Drugs 0.000 description 1
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010034707 chelidocystatin Proteins 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229960002542 dolutegravir Drugs 0.000 description 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- UUKPXXBDUCDZDA-KAFVXXCXSA-N favipiravir-RTP Chemical compound O=C1C(C(=O)N)=NC(F)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 UUKPXXBDUCDZDA-KAFVXXCXSA-N 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229950002031 galidesivir Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229940112586 kaletra Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940075124 molnupiravir Drugs 0.000 description 1
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940125674 nirmatrelvir Drugs 0.000 description 1
- LIENCHBZNNMNKG-OJFNHCPVSA-N nirmatrelvir Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C LIENCHBZNNMNKG-OJFNHCPVSA-N 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229950006081 taribavirin Drugs 0.000 description 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention provides a coronavirus caused by a mutant virus of the novel coronavirus containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (generic name: favipiravir, hereinafter referred to as compound A) or a salt thereof as an active ingredient. It relates to a therapeutic agent for infectious diseases.
- Non-Patent Document 1 The new coronavirus (SARS-CoV-2) (Non-Patent Document 1), which was first reported in China at the end of 2019, is an RNA virus belonging to the family Coronaviridae of the order Nidoviridae (Non-Patent Document 2). Infection with this virus is accompanied by acute respiratory symptoms such as fever, cough, and dyspnea (Non-Patent Document 1), and if exacerbated, pneumonia develops. As of May 12, 2021, the number of SARS-CoV-2-positive people in Japan exceeds 650,000, of which the number of deaths exceeds 10,000 (Non-Patent Document 3).
- Compound A is an antiviral drug created by FUJIFILM Toyama Chemical Co., Ltd. (formerly Toyama Chemical Co., Ltd.), and its efficacy is classified as "new or re-emerging influenza virus infection (however, other anti-influenza virus drugs In March 2014, it obtained manufacturing and marketing approval in Japan. Its mechanism of action is that the triphosphorylated form (T-705RTP) converted in vivo selectively inhibits viral RNA polymerase, so it is also effective against RNA viruses other than influenza virus. there is a possibility. In fact, it has been reported that it is effective against Ebola virus, Arenaviridae, and Bunyaviridae RNA viruses in vitro or in vivo (Non-Patent Documents 4, 5, 6).
- SARS-CoV-2 continues to accumulate genetic mutations at various sites in the genome, and many mutant viruses have been reported (https://nextstrain.org/ncov/global,https://cov- lineages.org/). Mutant viruses with high infection efficiency and mutant viruses that are concerned about the impact on vaccine efficacy have also emerged. (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html).
- Non-Patent Documents 7, 8, 9 Non-Patent Documents 7, 8, 9
- the object of the present invention is to provide a therapeutic agent for infectious diseases that is effective against the novel coronavirus mutant virus.
- compound A or a salt thereof can treat infectious diseases caused by mutant viruses of the novel coronavirus, and completed the present invention.
- a therapeutic agent for a coronavirus infection caused by a mutant virus of SARS-CoV-2 comprising 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient.
- [6] The therapeutic agent for coronavirus infection according to [1], wherein in the mutant virus, at least one mutation in the genetic information of the Wuhan-Hu-1 strain occurs in a gene encoding RNA-dependent RNA polymerase.
- the therapeutic agent for coronavirus infection according to [1], wherein the mutant virus is a virus with increased or decreased efficiency of human-to-human transmission compared to SARS-CoV-2.
- the therapeutic agent for coronavirus infection according to [1], wherein the mutant virus is a virus with increased immune escape ability compared to SARS-CoV-2.
- the therapeutic agent for coronavirus infection according to [1], wherein the mutant virus is a virus with increased or decreased resistance to a therapeutic drug for coronavirus infection compared to SARS-CoV-2.
- the mutant virus is B.1.1.7 (501Y.V1), B.1.351 (501Y.V2), P.1 (501Y.V3), B.1.427 (20C/S:452R), B.1.429 (20C /S:452R), B.1.526 (20C/S:484K), B.1.526.1 (20C), B.1.525 (20A/S:484K), P.2 (20J), B.1.617 (20A) , B.1.617.1 (20A/S: 154K), B.1.617.2 (20A/S: 478K), B.1.617.3 (20A), B.1.1.316, B.1.617 + S: V382L, Or the therapeutic agent for coronavirus infection according to [1], which is an experimentally or clinically isolated remdesivir-resistant coron
- the therapeutic agent for infectious diseases of the present invention is useful for treatments such as treatment or prevention of coronavirus infections caused by novel coronavirus mutant viruses.
- the numerical range indicated using “to” means the range including the numerical values before and after “to” as the minimum and maximum values, respectively.
- Compound A means 6-fluoro-3-hydroxy-2-pyrazinecarboxamide.
- salts in basic groups include, for example, salts with mineral acids such as hydrochloric, hydrobromic, nitric and sulfuric acids; formic, acetic, citric, oxalic, fumaric, maleic, succinic, malic, salts with organic carboxylic acids such as tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid. mentioned.
- Salts in acidic groups include, for example, salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and trimethylamine, triethylamine, tributylamine, pyridine, N,N- Nitrogen-containing compounds such as dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine, 1-ephenamine, N,N'-dibenzylethylenediamine and meglumine Examples include salts with organic bases.
- preferred salts include pharmacologically acceptable salts, and more preferred salts include salts with sodium or meglumine.
- compound A or a salt thereof has isomers (e.g., optical isomers, geometric isomers, tautomers, etc.)
- the present invention includes all isomers thereof, and hydrates, It includes solvates and all crystalline forms.
- coronavirus is an RNA virus belonging to the family Coronaviridae of the order Nidoviridae.
- An infectious disease caused by a coronavirus is a coronavirus infection.
- Novel coronavirus means SARS-CoV-2, which was reported at the end of 2019 among coronaviruses. The coronavirus disease caused by SARS-CoV-2 is also called COVID-19.
- Motant virus of novel coronavirus refers to the Wuhan-Hu-1 strain ( Accession No. NC_045512) means a virus in which at least part of the genetic information has been mutated.
- mutant virus is a term that includes both "mutant” and "mutant”.
- the mutant virus of the new coronavirus is posted on the website of the National Institute of Infectious Diseases, "About the new mutant strain of the new coronavirus (SARS-CoV-2), which is concerned about increased infectivity and transmissibility and changes in antigenicity. ” (https://www.niid.go.jp/niid/ja/2019-ncov/2551-cepr/10743-covid19-62.html). Examples include alpha, beta, gamma, delta, (old) kappa, lambda, mu, and AY.4.2.
- Structural proteins include S protein, M protein, E protein and N protein.
- Nonstructural proteins include primases, RNA-dependent RNA polymerases, helicases, exonucleases, ribonucleases, methyltransferases, proteases, and the like.
- mutant viruses in which mutations have occurred in the gene encoding the S protein of SARS-CoV-2 include B.1.1.7 (501Y.V1), B.1.351 (501Y.V2), and P.1 (501Y.V1). V3), B.1.427 (20C/S:452R), B.1.429 (20C/S:452R).
- Mutant viruses in which mutations have occurred in the genes encoding the M and E proteins of SARS-CoV-2, which are other structural proteins, include the literature (Jakhmola S, Indari O, Kashyap D, Varshney N, Das A, Manivannan et al. Mutational analysis of structural proteins of SARS-CoV-2. Heliyon. 2021;7:e06572.).
- the mutated virus of the new coronavirus is a virus whose viral properties have changed from SARS-CoV-2.
- the change in the nature of the virus means increased or decreased virulence, increased or decreased immune escape ability, increased or decreased efficiency of human-to-human transmission, increased or decreased resistance to therapeutic drugs for coronavirus infections, novel coronavirus Increased or decreased vaccine efficacy, increased or decreased viral replication can be mentioned.
- a hypervirulent or attenuated mutant virus refers to a virus whose pathogenicity to the host has changed.
- a virus with increased immune evasion ability refers to a virus that has changed so that it is difficult to be recognized as a foreign substance by the host and thus difficult to be eliminated by immunity.
- Viruses with increased or decreased human-to-human infection efficiency refer to viruses whose infection efficiency has changed due to changes in host cell binding ability to ACE2 or the like.
- a virus with increased or decreased resistance to a therapeutic drug for coronavirus infection refers to a virus whose structural protein or non-structural protein has changed in the site where the therapeutic drug acts.
- a virus with increased or decreased novel coronavirus vaccine efficacy refers to a virus with increased or decreased responsiveness to neutralizing antibodies acquired by the host through vaccination.
- a virus with increased or decreased viral replication refers to a virus with increased or decreased viral replication efficiency in host cells.
- Mutant viruses of the new coronavirus include the following. B.1.1.7 (501Y.V1), B.1.351 (501Y.V2), P.1 (501Y.V3), B.1.427 (20C/S:452R), B.1.429 (20C/S:452R) , B.1.526 (20C/S: 484K), B.1.526.1 (20C), B.1.525 (20A/S: 484K), P.2 (20J), B.1.617 (20A), B.1.617.
- the main amino acid mutation sites identified in the above-mentioned mutant viruses of the new coronavirus are as shown in Table 1 below.
- Mutant viruses of the new coronavirus include unknown mutant viruses such as unidentified mutant viruses and unappeared mutant viruses. Unknown variant viruses should be checked, for example, on the CDC website (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html), which is updated from time to time. can be done.
- Treatment means reducing or ameliorating one or more symptoms resulting from a particular disease that a subject is suffering from, as well as delaying the progression of that disease.
- it means reducing or improving symptoms such as fever, cough, and pneumonia, and for example, body temperature, percutaneous Means improvement in arterial oxygen saturation (SpO2) and chest imaging findings, or negative change in novel coronavirus mutation virus.
- Compound A or a salt thereof used in the present invention can be produced by a method known per se or by appropriately combining them. For example, it can be produced by the method described in International Publication No. 00/10569 pamphlet.
- Compound A has a tautomer, 6-fluoro-3-oxo-3,4-dihydro-2-pyrazinecarboxamide.
- Compound A or a salt thereof used in the present invention includes excipients, binders, disintegrants, disintegration inhibitors, anti-caking/adhering agents, lubricants, absorption/adsorption carriers, solvents, extenders, isotonic agents, solubilizers, emulsifiers, suspending agents, thickeners, coating agents, absorption accelerators, gelling/coagulation accelerators, light stabilizers, preservatives, moisture-proof agents, emulsifying/suspending/dispersing stabilizers
- Various pharmaceutical additives such as agents, anti-coloring agents, deoxidizers/antioxidants, flavoring/flavoring agents, coloring agents, foaming agents, anti-foaming agents, soothing agents, antistatic agents, buffers/pH adjusters, etc.
- oral formulations tablettes, capsules, powders, granules, fine granules, pills, suspensions, emulsions, liquid formulations, syrups, etc.
- injections eye drops
- transnasal formulations or transdermal formulations It can be a pharmaceutical preparation such as
- oral formulations or injections are preferable, oral formulations are more preferable, and tablets are even more preferable as dosage formulations for patients with infections caused by novel coronavirus mutant viruses.
- the above drugs are formulated by conventional methods.
- the administration method of compound A is not particularly limited, but is appropriately determined according to the form of the preparation, the patient's age, sex and other conditions, and the degree of the patient's symptoms.
- the dose of compound A is appropriately selected depending on the usage, patient age, sex, disease form, and other conditions. ⁇ 2400 mg may be administered once or several times a day. Compound A may be administered in multiple doses or in a single dose until the desired therapeutic effect is achieved. Administration is typically monitored and can be repeated as necessary.
- 1000 to 2400 mg of compound A may be administered to adults twice a day (first day) and 400 to 1200 mg twice a day (second day onwards).
- first day first day
- second day onwards second day onwards
- the administration interval of twice a day it is preferable to administer the second dose with an interval of at least 4 hours from the first dose, and it is more preferable to administer the second dose with an interval of 6 hours or more.
- the administration period is appropriately determined depending on the progression of symptoms, for example, up to 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, You can choose from 16 days, 17 days, 18 days, 19 days, 20 days, 21 days and 22 days. A maximum of 10 days, 13 days, 14 days, 22 days is preferred, and a maximum of 13 days, 14 days is more preferred.
- administration of compound A or a salt thereof can include concomitant drugs and/or concomitant therapies.
- a therapeutic agent for coronavirus infection can be used as a combination drug and/or combination therapy. Examples of therapeutic agents for coronavirus infections include the following agents.
- interferons (2) nucleic acid analogues (3) protease inhibitors (4) furin convertase cleavage inhibitors (5) reverse transcriptase inhibitors and/or other RNA polymerase inhibitors (6) neuraminidase inhibitors (7) ) angiotensin II receptor blockers (8) endosomal fusion inhibitors and/or endosomal alkalizing agents (9) AAK1, GAK and clathrin A, B, C (endocytosis) inhibitors (10) hemagglutinin esterase inhibitors (11 ) cytokines or inflammation inhibitors and modulators (12) cathepsin B inhibitors (13) cathepsin L inhibitors (14) helicase nsp13 inhibitors (15) MBL2 gene agonists (16) TP53 inhibitors (17) selective estrogen receptors Regulators (18) Steroid drugs (19) Other drugs (19) Other drugs
- Interferons include, for example, interferon ⁇ -2A, interferon ⁇ -2B, interferon ⁇ -n1, interferon ⁇ -n3, interferon ⁇ -1a and interferon ⁇ -1b. Interferon may be produced by combining methods known per se, or commercially available products may be used.
- Nucleic acid analogues include, for example, acyclovir, ganciclovir, ribavirin and taribavirin. It may be produced by combining methods known per se, or commercially available products may be used. Nucleic acid analogs may be produced by combining methods known per se, or commercially available ones may be used.
- protease inhibitors examples include indinavir, nelfinavir, saquinavir, camostat, lopinavir/ritonavir combination drug (product name: Kaletra), epigallocatechin gallate, kaempferol-7-glucoside, mycophenolic acid, darunavir, mercaptopurine, disulfiram , nafamostat and PF-07321332.
- Protease inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Furin convertase cleavage inhibitors include, for example, tenofovir disoproxil, dolutegravir, boceprevir, andrographolide, luteolin and baicalein. Furin convertase cleavage inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Reverse transcriptase inhibitors and/or RNA polymerase inhibitors include, for example, remdesivir, sofosbuvir, dactinomycin, galidesivir, baloxavir marboxil, molnupiravir, sanguibamycin and AT-527.
- Reverse transcriptase inhibitors and/or RNA polymerase inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Neuraminidase inhibitors include, for example, oseltamivir and zanamivir. Neuraminidase inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Angiotensin II receptor blockers include, for example, valsartan, telmisartan, losartan, irbesartan, azilsartan, olmesartan and emodin.
- Angiotensin II receptor blockers may be produced by combining methods known per se, or commercially available ones may be used.
- Endosome fusion inhibitors and/or endosomal alkalizing agents include, for example, baicalin, chloroquine, hydroxychloroquine, Griffithsin, quinine and lactoferrin. Endosome fusion inhibitors and/or endosome alkalinizing agents may be produced by combining methods known per se, or commercially available ones may be used.
- AAK1, GAK and clathrin A, B, C (endocytosis) inhibitors include, for example, baricitinib, sunitinib, erlotinib, fedratinib, gefitinib and silibinin.
- AAK1, GAK and clathrin A, B, C (endocytosis) inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Hemagglutinin esterase inhibitors include, for example, 3,4-dichloroisocoumarin.
- the hemagglutinin esterase inhibitor may be produced by combining methods known per se, or commercially available ones may be used.
- Cytokines or inflammation inhibitors and regulators include, for example, ligustrazine, statins, melatonin, eplerenone and methylprednisolone. Cytokines or inflammation inhibitors and regulators may be produced by combining methods known per se, or commercially available ones may be used.
- cathepsin B inhibitors examples include salvianolic acid B.
- Cathepsin B inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Cathepsin L inhibitors include, for example, MOL736, Chelidocystatin, astaxanthin, curcumin and vitamin D. Cathepsin L inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Helicase nsp13 inhibitors include, for example, valsartan, Bananin, Iodobananin, Vanillinbananin, Eubananin and Silbestrol.
- the helicase nsp13 inhibitor may be produced by combining methods known per se, or commercially available products may be used.
- MBL2 gene agonists include, for example, ⁇ -glucan and vitamin A.
- the MBL2 gene agonist may be produced by combining methods known per se, or commercially available products may be used.
- TP53 inhibitors include, for example, vitexin and gossypol.
- TP53 inhibitors may be produced by combining methods known per se, or commercially available ones may be used.
- Selective estrogen receptor modulators include, for example, toremifene and equilin. Selective estrogen receptor modulators may be produced by combining known methods, or commercially available ones may be used.
- Steroid drugs include, for example, ciclesonide and dexamethasone. Steroid drugs may be manufactured by combining methods known per se, or commercially available ones may be used.
- drugs include, for example, amantadine, foscarnet, triazavirine, umifenovir, rapamycin, everolimus, nitazoxanide, tizoxanide, caraphenol A, ivermectin, VIR-2703, tocilizumab, bamuranivimab, etecevimab, casilivimab/imdevimab, AZD7422, VIR-7831, VIR-7832 and BI 767551.
- Test example 1 Compound A is tested in a viral cell infection model.
- Vero E6 cells are used as the cells used.
- antiviral effects are evaluated by detecting cytopathic effects (CPE).
- CPE cytopathic effects
- cells to which the virus used is sensitive such as Vero, Vero 76, CaCo-2, Hep G2, and Calu-3, can also be used for evaluation.
- the antiviral effect can also be evaluated by the viral antigen-antibody method and the real-time PCR (polymerase chain reaction) method of extracting viral RNA from the viral culture supernatant.
- RNA virus select the novel coronavirus mutant virus B.1.1.7 (501Y.V1) and B.1.351 (501Y.V2) strains.
- test medium drug
- DMSO 0.5% DMSO
- CPE cytopathic effect
- the test will be conducted with 2 plates (8 cases for infected control and non-infected control) at 1/plate.
- the value obtained by subtracting the absorbance of the infected control from the absorbance of the non-infected control is taken as the complete inhibition value of virus growth, and the CPE inhibition rate in each test is calculated from the following formula.
- CPE inhibition rate 100 x [(absorbance when compound A is used) - (absorbance of infected control)] / [(absorbance of uninfected control) - (absorbance of infected control)]
- the FORECAST function (linear regression method) of Microsoft Office Excel 2016 is used to calculate the 50% CPE inhibitory concentration.
- compound A exhibits sensitivity to the novel coronavirus mutant virus B.1.1.7 (501Y.V1) and B.1.351 (501Y.V2) strains.
- Test example 2 As RNA viruses, novel coronavirus mutant viruses P.1 (501Y.V3), B.1.427 (20C/S: 452R), B.1.429 (20C/S: 452R), B.1.526 (20C/S: 484K) ), B.1.526.1 (20C), B.1.525 (20A/S: 484K), P.2 (20J), B.1.617 (20A), B.1.617.1 (20A/S: 154K), B .1.617.2 (20A/S:478K), B.1.617.3 (20A), B.1.1.316, B.1.617 + S:V382L, selected laboratory or clinically isolated remdesivir-resistant coronaviruses, By calculating the 50% inhibitory concentration of compound A in the same manner as in Test Example 1, it is confirmed that compound A exhibits susceptibility to various mutant viruses of the novel coronavirus.
- Test example 3 The drug susceptibility measurement of Compound A against the novel coronavirus and mutant viruses of the novel coronavirus was performed by the yield reduction method. USA_WA1/2020 (A strain) as a wild strain of the new coronavirus, hCoV-19/England/204820464/2020 (B.1.1.7 strain), hCoV-19/Japan/TY7- as a mutant virus of the new coronavirus Strain 503/2021 (P.1 lineage) was selected. After growing the virus in the presence of compound A at 3.2 to 1000 ⁇ M (common ratio 3), the amount of virus was measured at each concentration. The 90% effective concentration (EC 90 ) was calculated from the obtained virus amount.
- Virus growth> Plates were seeded with Vero 76 cells suspended in cell culture medium the day before virus infection. Vero76 cells cultured at 37° C. under 5% CO 2 conditions and formed into a monolayer the next day were used for the test. Virus culture medium containing compound A was added and pretreated for 1 hour at 37° C. under 5% CO 2 conditions. After removing the medium by aspiration, culture medium containing Compound A and virus solution (Multiplicity of Infection 0.01) were added to each well so that the final concentration was the predetermined concentration, and the mixture was kept at 37°C for 3 to 4 days under 5% CO 2 conditions. cultured. After the culture was completed, the culture supernatant of each well was transferred to a new plate and stored at -80°C until virus quantification.
- Virus culture medium containing compound A was added and pretreated for 1 hour at 37° C. under 5% CO 2 conditions. After removing the medium by aspiration, culture medium containing Compound A and virus solution (Multiplicity of Infection 0.01) were
- hCoV-19/Japan/TY2-312-P1/2020 (B.1.1 strain), which is a new coronavirus, was used as a standard strain, and hCoV-19, a mutant virus of the new coronavirus, was used.
- the EC 90 values of compound A against the standard and mutant strains above were 302 ⁇ M (first test) or 466 ⁇ M (second test), 359 ⁇ M (first test), 223 ⁇ M (second test), 306 ⁇ M (second test), respectively. ), 294 ⁇ M (first test), 491 ⁇ M (second test), and the EC 90 value of compound A for the mutant strain is 0.48 to 1.2 times the variation range compared to the standard strain. It was found that the same level of efficacy as the standard strain was exhibited against the mutant strain.
- Test example 4 ⁇ Cell culture> Vero E6 cells were seeded in 6-well assay plates and incubated for approximately 4 hours prior to Compound A treatment. ⁇ Pretreatment and potency test> Cells in each well were pretreated for about 4 hours with a compound A solution serially diluted at concentrations described below, and then infected with the novel coronavirus. SARS-2 WA1/2020 was used as a standard strain, and SARS-2 -9017 (delta) and SARS-2 -Omicron were used as novel coronavirus mutant viruses. Compound A potency was assessed by setting concentrations from 7.81 to 1000 ⁇ M (common ratio of 2) in wells on the plate.
- the multiplicity of infection of the virus solution to be added was 0.01, and the culture time after addition of the virus solution was 72 hours.
- the 50% cell culture infectious concentration (CCID 50 /mL (Log 10 )) was calculated by the Reed-Muench method.
- the EC 90 value was calculated by regression analysis of the Log 10 value of compound A concentration and the amount of virus (CCID 50 /mL (Log 10 )).
- the EC90 values of Compound A for the above standard and mutant strains are 125-250 ⁇ M (SARS-2 WA1/2020), 125-250 ⁇ M (SARS-2 -9017 (delta)), 62.5-125 ⁇ M ( SARS-2-Omicron), and it was found that compound A exhibited the same level of efficacy against the mutant strain as that of the standard strain.
- compound A is considered to be effective against the mutant virus of the novel coronavirus.
- a therapeutic agent for novel coronavirus mutant viruses containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient is useful in the field of the pharmaceutical industry.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[1]
6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミド又はその塩を有効成分として含有する、SARS-CoV-2の変異ウイルスに起因するコロナウイルス感染症の治療剤。
[2]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Sタンパクをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[3]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Mタンパクをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[4]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Eタンパクをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[5]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Nタンパクをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[6]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、RNA依存性RNAポリメラーゼをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[7]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、エキソヌクレアーゼをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[8]
前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、プロテアーゼをコードする遺伝子で生じている、[1]に記載のコロナウイルス感染症の治療剤。
[9]
前記変異ウイルスが、SARS-CoV-2と比較して、強毒化又は弱毒化したウイルスである、[1]に記載のコロナウイルス感染症の治療剤。
[10]
前記変異ウイルスが、SARS-CoV-2と比較して、ヒト―ヒト感染の効率が上昇又は低下したウイルスである、[1]に記載のコロナウイルス感染症の治療剤。
[11]
前記変異ウイルスが、SARS-CoV-2と比較して、免疫逃避能が上昇したウイルスである、[1]に記載のコロナウイルス感染症の治療剤。
[12]
前記変異ウイルスが、SARS-CoV-2と比較して、コロナウイルス感染症治療薬に対する耐性が上昇又は低下したウイルスである、[1]に記載のコロナウイルス感染症の治療剤。
[13]
前記変異ウイルスが、SARS-CoV-2と比較して、新型コロナウイルスワクチンの有効性が上昇又は低下したウイルスである、[1]に記載のコロナウイルス感染症の治療剤。
[14]
前記変異ウイルスが、B.1.1.7(501Y.V1)、B.1.351(501Y.V2), P.1(501Y.V3)、B.1.427(20C/S:452R)、B.1.429(20C/S:452R)、B.1.526(20C/S:484K)、B.1.526.1(20C)、B.1.525(20A/S:484K)、P.2(20J)、B.1.617(20A)、B.1.617.1(20A/S:154K)、B.1.617.2(20A/S:478K)、B.1.617.3(20A)、B.1.1.316、B.1.617 + S:V382L、又は実験又は臨床で分離されたレムデシビル耐性コロナウイルスである、[1]に記載のコロナウイルス感染症の治療剤。
本明細書において特に断らない限り、各用語は次の意味を有する。
塩基性基における塩としては、例えば、塩酸、臭化水素酸、硝酸及び硫酸などの鉱酸との塩;ギ酸、酢酸、クエン酸、シュウ酸、フマル酸、マレイン酸、コハク酸、リンゴ酸、酒石酸、アスパラギン酸、トリクロロ酢酸及びトリフルオロ酢酸などの有機カルボン酸との塩;ならびにメタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、メシチレンスルホン酸及びナフタレンスルホン酸などのスルホン酸との塩が挙げられる。
「新型コロナウイルス」とは、コロナウイルスの内、2019年末に報告されたSARS-CoV-2を意味する。SARS-CoV-2に起因するコロナウイルス感染症をCOVID-19とも称する。
「新型コロナウイルスの変異ウイルス」とは、NCBIサイト(https://www.ncbi.nlm.nih.gov/sars-cov-2/)でReference株として定義されているWuhan-Hu-1株(Accession No. NC_045512)の遺伝情報の少なくとも一部が変異したウイルスを意味する。ここで「変異ウイルス」は、「変異株」と「変異種」のいずれも包含する語である。
B.1.1.7(501Y.V1)、B.1.351(501Y.V2), P.1(501Y.V3)、B.1.427(20C/S:452R)、B.1.429(20C/S:452R)、B.1.526(20C/S:484K)、B.1.526.1(20C)、B.1.525(20A/S:484K)、P.2(20J)、B.1.617(20A)、B.1.617.1(20A/S:154K)、B.1.617.2(20A/S:478K)、B.1.617.3(20A)、B.1.1.316、B.1.617 + S:V382L、実験又は臨床で分離されたレムデシビル耐性コロナウイルス
上記薬剤は、通常の方法により製剤化される。
1日2回の投与間隔は、1回目の投与から少なくとも4時間以上の間隔を空けて2回目を投与することが好ましく、6時間以上の間隔を空けて2回目を投与することがより好ましい。
投与期間は、症状の推移により適宜決定されるが、例えば、最長5日間、6日間、7日間、8日間、9日間、10日間、11日間、12日間、13日間、14日間、15日間、16日間、17日間、18日間、19日間、20日間、21日間及び22日間から選択できる。最長10日間、13日間、14日間、22日間が好ましく、最長13日間、14日間がより好ましい。
(1)インターフェロン
(2)核酸アナログ
(3)プロテアーゼ阻害剤
(4)フーリンコンベルターゼ開裂阻害剤
(5)逆転写酵素阻害剤及び/又は他のRNAポリメラーゼ阻害剤
(6)ノイラミニダーゼ阻害剤
(7)アンジオテンシンII受容体ブロッカー
(8)エンドソーム融合阻害剤及び/又はエンドソームアルカリ化剤
(9)AAK1、GAK及びクラスリンA,B,C(エンドサイトーシス)阻害剤
(10)ヘマグルチニンエステラーゼ阻害剤
(11)サイトカイン又は炎症阻害剤及び調整剤
(12)カテプシンB阻害剤
(13)カテプシンL阻害剤
(14)ヘリカーゼnsp13阻害剤
(15)MBL2遺伝子アゴニスト
(16)TP53阻害剤
(17)選択的エストロゲン受容体調整剤
(18)ステロイド薬
(19)その他薬剤
化合物Aについて、ウイルスの細胞感染モデルで試験を行う。使用細胞として、Vero E6細胞を用いる。具体的には、抗ウイルス効果を細胞変性効果(cytopathic effect; CPE)の検出により評価する。なお、使用細胞は、Vero E6に加え、使用ウイルスが感受性を示すVero、Vero 76、CaCo-2、Hep G2、Calu-3などを用いて評価することも可能である。抗ウイルス効果は、CPE法に加え、ウイルス抗原抗体法やウイルス培養上清からウイルスRNAを抽出しリアルタイムPCR(polymerase chain reaction)法等で評価することも可能である。
培養液10%ウシ胎児血清添加イーグルMEM/カナマイシン60μg/mL(イーグルMEM/カナマイシン)培地中、5%二酸化炭素条件下、37℃で継代培養されているアフリカミドリザル腎Vero E6細胞をエチレンジアミン四酢酸トリプシン法によって剥離し、同培地で100μLに2×104個の細胞を含むように調製した懸濁液を96ウェルプレートに播種する。5%二酸化炭素条件下、37℃で一夜培養し、単層となったVero E6細胞を得る。
試験培地として、2%ウシ胎児血清添加イーグルMEM/カナマイシン培地を用いる。(1)で得られたVero E6細胞の培養上清を取り除き、各ウェルに、以下(A)、(B)を加え、5%二酸化炭素条件下、37℃で1~2時間培養する。
(A)試験培地で最終的に感染多重度が0.1~10になるように調製した新型コロナウイルスの変異ウイルス液を100μL
(B)設定濃度の2倍濃度の化合物A、各設定濃度の組み合わせを含む0.5%DMSO含有試験培地(薬剤)を100μL
化合物A設定濃度(μM):
0, 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000, 5000, 8000, 10000
SARS-CoV-2の増殖に伴って認められるCPEを、以下の方法で判定する。
RNAウイルスとして、新型コロナウイルスの変異ウイルス P.1(501Y.V3)、B.1.427(20C/S:452R)、B.1.429(20C/S:452R)、B.1.526(20C/S:484K)、B.1.526.1(20C)、B.1.525(20A/S:484K)、P.2(20J)、B.1.617(20A)、B.1.617.1(20A/S:154K)、B.1.617.2(20A/S:478K)、B.1.617.3(20A)、B.1.1.316、B.1.617 + S:V382L、実験又は臨床で分離されたレムデシビル耐性コロナウイルスを選択し、上記試験例1と同様の手法により、化合物Aの50%阻害濃度を算出することにより、化合物Aが、新型コロナウイルスの種々の変異ウイルスに感受性を示すことが確認される。
〈薬剤感受性測定〉
新型コロナウイルス及び新型コロナウイルスの変異ウイルスに対する化合物Aの薬剤感受性測定は、yield reduction法により行った。新型コロナウイルスの野生株として、USA_WA1/2020(A系統)、新型コロナウイルスの変異ウイルスとして、hCoV-19/England/204820464/2020(B.1.1.7系統)、hCoV-19/Japan/TY7-503/2021(P.1系統)株を選択した。3.2~1000 μM(公比3)の化合物A存在下でウイルスを増殖させた後、各濃度におけるウイルス量の測定を行った。得られたウイルス量より、90%有効濃度(90% effective concentration ; EC90)を算出した。
ウイルス感染前日に、細胞培養培地に懸濁したVero 76細胞をプレートに播種した。5% CO2条件下37℃で培養し、翌日に単層となったVero76細胞を試験に使用した。化合物Aを含むウイルス培養培地を添加し、5% CO2条件下37℃で1時間前処理した。培地を吸引除去後、各ウェルに終濃度が所定濃度になるように化合物Aを含む培養培地及びウイルス液(Multiplicity of Infection 0.01)を添加し、5% CO2条件下37℃で3~4日間培養した。培養終了後、各ウェルの培養上清を新しいプレートに分取し、ウイルス定量まで-80℃で保存した。
ウイルス感染前日に、細胞培養培地に懸濁したVero 76細胞をプレートに播種した。〈ウイルス増殖〉で取得したウイルス培養液を公比10で段階希釈後、希釈ウイルス液をVero 76細胞に添加し(n=4)、5% CO2条件下37℃で3~4日間培養した。培養終了後、各ウェルのCPEの有無を確認後、50%細胞培養感染濃度(CCID50/mL(Log10))をReed-Muench法により算出した。また、EC90値は化合物A濃度のLog10値とウイルス量(CCID50/mL(Log10))を回帰分析し算出した。
〈細胞培養〉
Vero E6細胞を6ウェルアッセイプレートに播種し、化合物Aで処理する前に約4時間インキュベートした。
〈前処理及び力価試験〉
後述する濃度で段階希釈した化合物A溶液で各ウェルの細胞を約4時間前処理した後、新型コロナウイルスに感染させた。標準株としてSARS-2 WA1/2020を、新型コロナウイルスの変異ウイルスとしてSARS-2 -9017 (delta)及びSARS-2 -Omicronを用いた。化合物Aの力価は、プレート上のウェルで7.81~1000 μM(公比2)濃度を設定することによって評価した。添加するウイルス液のMultiplicity of Infectionは0.01、ウイルス液を添加後の培養時間は72時間とした。
感染した各ウェルから培養上清液を採取し、公比10で段階希釈後、単層となったVeroE6細胞に添加し(n=4)、培養した。。明確なCPEを観察後、50%細胞培養感染濃度(CCID50/mL(Log10))をReed-Muench法により算出した。また、EC90値は化合物A濃度のLog10値とウイルス量(CCID50/mL(Log10))を回帰分析し算出した。
Claims (14)
- 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミド又はその塩を有効成分として含有する、SARS-CoV-2の変異ウイルスに起因するコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Sタンパクをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Mタンパクをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Eタンパクをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、Nタンパクをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、RNA依存性RNAポリメラーゼをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、エキソヌクレアーゼをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスにおいて、Wuhan-Hu-1株の遺伝情報の変異の少なくとも一つが、プロテアーゼをコードする遺伝子で生じている、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスが、SARS-CoV-2と比較して、強毒化又は弱毒化したウイルスである、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスが、SARS-CoV-2と比較して、ヒト―ヒト感染の効率が上昇又は低下したウイルスである、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスが、SARS-CoV-2と比較して、免疫逃避能が上昇したウイルスである、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスが、SARS-CoV-2と比較して、コロナウイルス感染症治療薬に対する耐性が上昇又は低下したウイルスである、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスが、SARS-CoV-2と比較して、新型コロナウイルスワクチンの有効性が上昇又は低下したウイルスである、請求項1に記載のコロナウイルス感染症の治療剤。
- 前記変異ウイルスが、B.1.1.7(501Y.V1)、B.1.351(501Y.V2), P.1(501Y.V3)、B.1.427(20C/S:452R)、B.1.429(20C/S:452R)、B.1.526(20C/S:484K)、B.1.526.1(20C)、B.1.525(20A/S:484K)、P.2(20J)、B.1.617(20A)、B.1.617.1(20A/S:154K)、B.1.617.2(20A/S:478K)、B.1.617.3(20A)、B.1.1.316、B.1.617 + S:V382L、又は実験又は臨床で分離されたレムデシビル耐性コロナウイルスである、請求項1に記載のコロナウイルス感染症の治療剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280042533.9A CN117479940A (zh) | 2021-05-14 | 2022-05-12 | 针对新冠病毒的变异病毒的感染症治疗剂 |
JP2023521236A JPWO2022239823A1 (ja) | 2021-05-14 | 2022-05-12 | |
EP22807522.2A EP4338736A1 (en) | 2021-05-14 | 2022-05-12 | Agent for treating infectious diseases against mutant viruses of novel coronavirus |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021082834 | 2021-05-14 | ||
JP2021-082834 | 2021-05-14 | ||
JP2021-101341 | 2021-06-18 | ||
JP2021101341 | 2021-06-18 | ||
JP2021-180064 | 2021-11-04 | ||
JP2021180064 | 2021-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022239823A1 true WO2022239823A1 (ja) | 2022-11-17 |
Family
ID=84029704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/020028 WO2022239823A1 (ja) | 2021-05-14 | 2022-05-12 | 新型コロナウイルスの変異ウイルスに対する感染症治療剤 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4338736A1 (ja) |
JP (1) | JPWO2022239823A1 (ja) |
WO (1) | WO2022239823A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000010569A1 (fr) | 1998-08-20 | 2000-03-02 | Toyama Chemical Co., Ltd. | Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux |
-
2022
- 2022-05-12 WO PCT/JP2022/020028 patent/WO2022239823A1/ja active Application Filing
- 2022-05-12 JP JP2023521236A patent/JPWO2022239823A1/ja active Pending
- 2022-05-12 EP EP22807522.2A patent/EP4338736A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000010569A1 (fr) | 1998-08-20 | 2000-03-02 | Toyama Chemical Co., Ltd. | Derives heterocycliques azotes de carboxamide ou certains de leurs sels et antiviraux les contenant les deux |
Non-Patent Citations (19)
Title |
---|
"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2", NAT MICROBIOL, vol. 5, 2020, pages 536 - 44 |
"Kokunai no hassei jokyo nado (in Japanese) (Situation of occurrences etc.) [Internet", TOKYO: MINISTRY OF HEALTH, LABOUR AND WELFARE, 12 May 2021 (2021-05-12) |
AGOSTINI MLANDRES ELSIMS ACGRAHAM RLSHEAHAN TPLU X ET AL.: "Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease", MBIO, vol. 9, 2018, pages e00221 - 18 |
ASSIS LETÍCIA CRISTINA, DE CASTRO ALEXANDRE ALVES, DE JESUS JOÃO PAULO ALMIRÃO, DA CUNHA ELAINE FONTES FERREIRA, NEPOVIMOVA EUGENI: "Theoretical insights into the effect of halogenated substituent on the electronic structure and spectroscopic properties of the favipiravir tautomeric forms and its implications for the treatment of COVID-19", RSC ADVANCES, vol. 11, no. 56, 28 October 2021 (2021-10-28), pages 35228 - 35244, XP093004803, DOI: 10.1039/D1RA06309J * |
BUDHIRAJA SANDEEP, INDRAYAN ABHAYA, AGGARWAL MONA, JHA VINITA, JAIN DINESH, TARAI BANSIDHAR, DAS POONAM, AGGARWAL BHARAT, MISHRA R: "Differentials in the characteristics of COVID-19 cases in Wave-1 and Wave-2 admitted to a network of hospitals in North India", MEDRXIV, 27 June 2021 (2021-06-27), XP093004814, [retrieved on 20221205], DOI: 10.1101/2021.06.24.21259438 * |
DRIOUICH JEAN-SÉLIM, COCHIN MAXIME, LINGAS GUILLAUME, MOUREAU GRÉGORY, TOURET FRANCK, PETIT PAUL-RÉMI, PIORKOWSKI GÉRALDINE, BARTH: "Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model", NATURE COMMUNICATIONS, vol. 12, no. 1, XP093004799, DOI: 10.1038/s41467-021-21992-w * |
GHASEMNEJAD-BERENJI MORTEZA, PASHAPOUR SARVIN: "Favipiravir and COVID-19: A Simplified Summary", DRUG RESEARCH, GEORG THIEME VERLAG, DE, vol. 71, no. 03, 1 March 2021 (2021-03-01), DE , pages 166 - 170, XP055790662, ISSN: 2194-9379, DOI: 10.1055/a-1296-7935 * |
GOWEN BB, WONG MH, JUNG KH, SANDERS AB, MENDENHALL M, BAILEY KW: "In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.", ANTIMICROB AGENTS CHEMOTHER, vol. 51, 2007, pages 3168 - 76 |
JAKHMOLA SINDARI OKASHYAP DVARSHNEY NDAS AMANIVANNAN ET AL.: "Mutational analysis of structural proteins of SARS-CoV-2", HELIYON, vol. 7, no. NC_045512, 2021, pages e06572 |
MARTINOT MJARY AFAFI-KREMER SLEDUCQ VDELAGREVERIE HGARNIER M ET AL.: "Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19", CLIN INFECT DIS, 2020 |
MENDENHALL MRUSSELL ASMEE DFHALL JOSKIRPSTUNAS RFURUTA Y ET AL.: "Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever", PLOS NEGL TROP DIS, vol. 5, 2011, pages e1342 |
OESTEREICH LLUDTKE AWURR SRIEGER TMUNOZ-FONTELA CGUNTHER S: "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model", ANTIVIRAL RES, vol. 105, 2014, pages 17 - 21, XP055265228, DOI: 10.1016/j.antiviral.2014.02.014 |
PADHI ADITYA K., DANDAPAT JAGNESHWAR, SAUDAGAR PRAKASH, UVERSKY VLADIMIR N., TRIPATHI TIMIR: "Interface‐based design of the favipiravir‐binding site in SARS‐CoV‐2 RNA‐dependent RNA polymerase reveals mutations conferring resistance to chain termination", FEBS LETTERS, ELSEVIER, AMSTERDAM., NL, vol. 595, no. 18, 1 September 2021 (2021-09-01), NL , pages 2366 - 2382, XP093004812, ISSN: 0014-5793, DOI: 10.1002/1873-3468.14182 * |
RAMAN RENUKA, PATEL KRISHNA J., RANJAN KISHU: "COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies", BIOMOLECULES, vol. 11, no. 7, pages 993, XP093004805, DOI: 10.3390/biom11070993 * |
SHINADA KANAKO, SATO TAKASHI, MORIYAMA SAYA, ADACHI YU, SHINODA MASAHIRO, OTA SHINICHIRO, MORIKAWA MIWA, MINESHITA MASAMICHI, MATS: "Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir", VIRUSES, vol. 14, no. 4, 24 March 2022 (2022-03-24), pages 670, XP093004810, DOI: 10.3390/v14040670 * |
SZEMIEL ET AL.: "In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2", BIORXIV 2021 |
WANG CHORBY PWHAYDEN FGGAO GF: "A novel coronavirus outbreak of global health concern", LANCET, vol. 395, 2020, pages 470 - 3, XP086050316, DOI: 10.1016/S0140-6736(20)30185-9 |
WU CAN-RONG, YIN WAN-CHAO, JIANG YI, XU H. ERIC: "Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, GB, vol. 43, no. 12, 1 December 2022 (2022-12-01), GB , pages 3021 - 3033, XP093004809, ISSN: 1671-4083, DOI: 10.1038/s41401-021-00851-w * |
ZHOU SHUNTAI, HILL COLLIN S, SARKAR SANJAY, TSE LONGPING V, WOODBURN BLAIDE M D, SCHINAZI RAYMOND F, SHEAHAN TIMOTHY P, BARIC RALP: "β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US, vol. 224, no. 3, 2 August 2021 (2021-08-02), US , pages 415 - 419, XP093004801, ISSN: 0022-1899, DOI: 10.1093/infdis/jiab247 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022239823A1 (ja) | 2022-11-17 |
EP4338736A1 (en) | 2024-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dos Santos | Natural history of COVID-19 and current knowledge on treatment therapeutic options | |
Khorramdelazad et al. | Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection | |
Matsuyama et al. | An aberrant STAT pathway is central to COVID-19 | |
Duwe et al. | A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1 | |
US20230210848A1 (en) | Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug | |
Fang et al. | Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice | |
TW202139987A (zh) | 維多氟地莫司(Vidofludimus)用於治療或預防病毒性疾病 | |
Dahal et al. | EGR1 upregulation following Venezuelan equine encephalitis virus infection is regulated by ERK and PERK pathways contributing to cell death | |
Dobosh et al. | Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes | |
KR20200103056A (ko) | 고사이토카인혈증 및 중증 인플루엔자의 치료 또는 예방을 위한 방법 및 화합물 | |
Rajaiah et al. | Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19 | |
Hong et al. | Remdesivir as a broad-spectrum antiviral drug against COVID-19. | |
KR20210146992A (ko) | 인플루엔자 바이러스 전염을 예방하기 위한 화합물 및 방법 | |
Fang et al. | Induction and modulation of the unfolded protein response during porcine deltacoronavirus infection | |
Schulz et al. | Influenza virus-induced paracrine cellular senescence of the lung contributes to enhanced viral load | |
Tong et al. | Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions | |
Hurt et al. | Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs | |
Wu et al. | Pterostilbene effectively inhibits influenza A virus infection by promoting the type I interferon production | |
WO2022239823A1 (ja) | 新型コロナウイルスの変異ウイルスに対する感染症治療剤 | |
EP3934653B1 (en) | Azelastine as antiviral treatment | |
WO2021164689A1 (zh) | 奈非那韦在制备防治新冠肺炎药物中的应用 | |
CN117479940A (zh) | 针对新冠病毒的变异病毒的感染症治疗剂 | |
CN114732804A (zh) | 一种含大麻二酚cbd提取物在新型冠状病毒肺炎的应用 | |
Piacentini et al. | The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein | |
Fiorino et al. | The rationale for a multi-step therapeutic approach based on antivirals and drugs with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22807522 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023521236 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18559873 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280042533.9 Country of ref document: CN Ref document number: 2022807522 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022807522 Country of ref document: EP Effective date: 20231214 |